Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa dose-escalation study of inhaled H057 in mild to moderate ARDS
ChiCTR2500098895Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of H-057 in acute respiratory distress syndrome (ARDS) (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Proportion of patients with PaO2/FiO2 greater than 300 mmHg sustained for at least 12 hours. Started Mar 2025; status: recruiting.
02
Drugs
H-057
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2500098895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098895.